Citations

Clear

75 citation(s) found for "Wu, Xiaosheng".

Faculty Opinions recommendation of Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation.
Jelinek, Diane F., Wu, Xiaosheng

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 17, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.1163894.626623 Get It

Faculty Opinions recommendation of The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia.
Jelinek, Diane F., Wu, Xiaosheng

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 17, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.1168014.630121 Get It

Faculty Opinions recommendation of SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.
Jelinek, Diane F., Wu, Xiaosheng

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 1, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.13410996.14782113 Get It

Faculty Opinions recommendation of The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Jelinek, Diane F., Wu, Xiaosheng

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | July 31, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.14264142.15777309 Get It

Faculty Opinions recommendation of AID-driven deletion causes immunoglobulin heavy chain locus suicide recombination in B cells.
Jelinek, Diane F., Wu, Xiaosheng

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | July 31, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.714997805.792003168 Get It

In utero cell transfer between porcine littermates
McConico, Andrea L., Butters, Kim A., Lien, Karen, Wu, Xiaosheng , Platt, Jeffrey L. , Ogle, Brenda M. , Knudsen, Bruce E.

Mayo Clinic

Reproduction, Fertility and Development | January 4, 2011 | Volume: 23 | Issue: 2 | Pages: 297-302

10.1071/rd10165 | PMID 21211462 Get It

Trafficking of cells between mother and fetus during the course of normal pregnancy is well documented. Similarly, cells are known to travel between twins that share either a placenta (i.e. monozygotic) or associated chorion (i.e. monochorionic). Transferred cells are thought to be channelled via the vessels of the placenta or vascular connections established via the chorion and the long-term presence of these cells (i.e. microchimerism) can have important consequences for immune system function and reparative capacity of the host. Whether cells can be transferred between twins with separate placentas and separate chorions (i.e. no vascular connections between placentas) has not been investigated nor have the biological consequences of such a transfer. In the present study, we tested the possibility of this type of cell transfer by injecting human cord blood-derived cells into a portion of the littermates of swine and probing for human cells in the blood and tissues of unmanipulated littermates. Human cells were detected in the blood of 78% of unmanipulated littermates. Human cells were also detected in various tissues of the unmanipulated littermates, including kidney (56%), spleen (33%), thymus (11%) and heart (22%). Human cells were maintained in the blood until the piglets were sacrificed (8 months after birth), suggesting the establishment of long-term microchimerism. Our findings show that the transfer of cells between fetuses with separate placentas and separate chorions is significant and thus such twins may be subject to the same consequences of microchimerism as monozygotic or monochorionic counterparts.
LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis
Gutierrez, Albert, Tschumper, Renee C. , Wu, Xiaosheng , Eckel‐Passow, Jeanette E. , Huddleston, P.M. , Jelinek, Diane F., Shanafelt, Tait D. , Slager, Susan L. , Kay, Neil E. , Huddleston, Paul M

Mayo Clinic

Blood | July 2, 2010 | Volume: 116 | Issue: 16 | Pages: 2975-2983

10.1182/blood-2010-02-269878 | PMID 20595513 Get It

Abstract The canonical Wnt signaling pathway is pathogenic in a variety of cancers. We previously identified aberrant expression of the Wnt pathway transcription factor and target gene lymphoid enhancer binding factor-1 (LEF1) in chronic lymphocytic leukemia (CLL). This suggested that the Wnt signaling pathway has a role in the biology of CLL. In this study, we performed a Wnt pathway analysis using gene expression profiling and identified aberrant regulation of Wnt pathway target genes, ligands, and signaling members in CLL cells. Furthermore, we identified aberrant protein expression of LEF-1 specifically in CLL but not in normal mature B-cell subsets or after B-cell activation. Using the T cell–specific transcription factor/LEF (TCF/LEF) dual luciferase reporter assay, we demonstrated constitutive Wnt pathway activation in CLL, although the pathway was inactive in normal peripheral B cells. Importantly, LEF-1 knockdown decreased CLL B-cell survival. We also identified LEF-1 expression in CD19+/CD5+ cells obtained from patients with monoclonal B-cell lymphocytosis, suggesting a role for LEF-1 early in CLL leukemogenesis. This study has identified the constitutive activation and prosurvival function of LEF-1 and the Wnt pathway in CLL and uncovered a possible role for these factors in the preleukemic state of monoclonal B-cell lymphocytosis.
The Structure of the TNFRSF13C Promoter Enables Differential Expression of BAFF-R during B Cell Ontogeny and Terminal Differentiation
Mihalcik, Stephen A. , Huddleston, P.M. , Wu, Xiaosheng , Jelinek, Diane F., Huddleston, Paul M

Mayo Clinic

The Journal of Immunology | June 17, 2010 | Volume: 185 | Issue: 2 | Pages: 1045-1054

10.4049/jimmunol.1001120 | PMID 20554963 Get It

Abstract The B cell-activating factor of the TNF family receptor (BAFF-R), encoded by the TNFRSF13C gene, is critically important for transitional B cell survival to maturity. Thus, ligation of BAFF-R by BAFF delivers a potent survival signal. Reports implicating the BAFF/BAFF-R signaling axis in the pathogenesis of autoimmune human diseases and B lineage malignancies have largely prompted studies focusing on BAFF expression; however, there is an equally critical need to better understand BAFF-R expression. Initial BAFF-R expression, although characterized in murine B cells, has not yet been reported in human B lymphopoiesis. In this study, we first demonstrate that BAFF-R expression is absent from early precursors and is acquired by bone marrow B cells newly expressing the BCR. We next focused on identifying the specific genomic region that controls BAFF-R expression in mature B cells (i.e., the TNFRSF13C promoter). To accomplish this, we used in silico tools examining interspecies genomic conservation in conjunction with reporter constructs transfected into malignant B and plasma cell lines. DNase protection assays using nuclear extracts from BAFF-R–expressing cells suggested potential regulatory sites, which allowed the generation of EMSA probes that bound NFs specific to BAFF-R–expressing cells. With a more stringent analysis of interspecies homology, these assays identified a site at which a single nucleotide substitution could distinctly impact promoter activity. Finally, chromatin immunoprecipitation assays revealed the in vivo binding of the specific transcription factor c-Rel to the most proximal genomic region, and c-Rel small interfering RNA transfections in BAFF-R–expressing lines demonstrated a coincident knockdown of both c-Rel and BAFF-R mRNA.
Response: Cautious interpretation of assessment of AID variant activities using cells with endogenous AID expression
Wu, Xiaosheng , Jelinek, Diane F.

Mayo Clinic

Blood | February 19, 2009 | Volume: 113 | Issue: 8 | Pages: 1864-1864

10.1182/blood-2008-11-187732 Get It

Alternative splicing regulates activation-induced cytidine deaminase (AID): implications for suppression of AID mutagenic activity in normal and malignant B cells
Wu, Xiaosheng , Darce, Jaime, Chang, Sook Kyung, Nowakowski, Grzegorz S. , Jelinek, Diane F.

Mayo Clinic

Blood | August 7, 2008 | Volume: 112 | Issue: 12 | Pages: 4675-4682

10.1182/blood-2008-03-145995 | PMID 18684869 Get It

Abstract The mutagenic enzyme activation-induced cytidine deaminase (AID) is required for immunoglobulin class switch recombination (CSR) and somatic hypermutation (SHM) in germinal center (GC) B cells. Deregulated expression of AID is associated with various B-cell malignancies and, currently, it remains unclear how AID activity is extinguished to avoid illegitimate mutations. AID has also been shown to be alternatively spliced in malignant B cells, and there is limited evidence that this also occurs in normal blood B cells. The functional significance of these splice variants remains unknown. Here we show that normal GC human B cells and blood memory B cells similarly express AID splice variants and show for the first time that AID splicing variants are singly expressed in individual normal B cells as well as malignant B cells from chronic lymphocytic leukemia patients. We further demonstrate that the alternative AID splice variants display different activities ranging from inactivation of CSR to inactivation or heightened SHM activity. Our data therefore suggest that CSR and SHM are differentially switched off by varying the expression of splicing products of AID at the individual cell level. Most importantly, our findings suggest a novel tumor suppression mechanism by which unnecessary AID mutagenic activities are promptly contained for GC B cells.